Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-interval cyclophosphamide versus methotrexate for refractory idiopathic inflammatory myopathy
ChiCTR2100049656Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Autoimmune Myopathies comparing CTX group with MTX group (2 arms). Primary endpoint: Proportion of patients with mild improvement at 12 months. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
cyclophosphamidemethotrexate
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on ChiCTR2100049656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049656.